Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Is Slipping Today

By Keith Speights – Aug 5, 2020 at 11:59AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

News from two rivals overshadowed Moderna's positive Q2 update.

What happened

Shares of Moderna (MRNA -0.58%) are slumping today, down 3.9% as of 11:29 a.m. EDT. The biotech reported its second-quarter results before the market opened. However, they don't appear to be the reason behind the decline in Moderna's stock. Instead, the main factors seem to be news from two rivals in the race to develop a COVID-19 vaccine: Novavax (NVAX 0.60%) and Johnson & Johnson (JNJ 0.05%).

Novavax announced positive phase 1 results for its COVID-19 vaccine candidate NVX-CoV2373 after the market closed on Tuesday. Earlier today, Johnson & Johnson announced a deal with the U.S. government to supply 100 million doses of its experimental coronavirus vaccine Ad26.COV2.S for around $1 billion.

Gloved hands holding four vials labeled "coronavirus vaccine"

Image source: Getty Images.

So what

Moderna beat Wall Street estimates on both the top and bottom lines in the second quarter. Late-stage testing of COVID-19 vaccine candidate mRNA-1273 is on track. The company even reported that it has received around $400 million of customer deposits related to deals to potentially supply mRNA-1273. This was all good news that wouldn't cause its shares to dip. 

But Novavax's positive phase 1 results could mean that mRNA-1273 might play second fiddle to NVX-CoV2373. Analysts gushed about the development. Cantor Fitzgerald's Charles Duncan hinted that Novavax's vaccine could be "class-leading." J.P. Morgan's Eric Joseph expressed his view that the immune response for NVX-CoV2373 "looks best-in-class."

How did Johnson & Johnson's deal negatively impact Moderna? It comes down to pricing. J&J is getting around $10 per dose in its deal with the U.S. government. Moderna said in its Q2 conference call that its small-volume agreements so far have fetched between $32 and $37 per dose for mRNA-1273. J&J's at-cost price could put pressure on Moderna to go with a lower price per dose in a supply agreement with the U.S. government.

Now what

What really matters for Moderna is how well mRNA-1273 performs in late-stage clinical testing. The biotech stock will almost certainly soar if those phase 3 results are overwhelmingly positive. However, it will be several months before any data is available. And today's slide underscores that competitors' success and pricing will matter quite a bit for Moderna, too.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna Inc. Stock Quote
Moderna Inc.
MRNA
$175.38 (-0.58%) $-1.02
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$177.33 (0.05%) $0.09
Novavax Stock Quote
Novavax
NVAX
$16.64 (0.60%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.